Servier received the European Commission's decision to registry vorasydenib – the first targeted molecular therapy for patients with Grade II glioma with mutation of IDH genes Worasydenib was authorised by the European Commission as the first molecular-oriented therapy in the European Union to be utilized in the treatment of Grade II glioma with mutation of the IDH genes. In a key pre-registration survey [...]
